Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.49 |
| ▸ | PGK2 | P07205 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31140757 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL30901676 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL30284387 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL25382883 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL28678580 | 0.91 | ADORA3 (0.55) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL9569366 | 0.90 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL26780511 | 0.90 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL23927951 | 0.90 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL31140789 | 0.90 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPGK1 | |
| SCHEMBL26039175 | 0.90 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3897668-B1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA PHARMACEUTICALS INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240261316-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. | 2024-08-08 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220347200-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220347199-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| CN-113784721-A | High activity compound for resisting COVID-19 | 阿堤亚制药公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3897668-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347199-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, ACE2, MTAP | ADORA3 105/4885ADORA1 132/4885ADORA2A 34/4885 |
| US-20220347200-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, ACE2, MTAP | ADORA3 105/4885ADORA1 132/4885ADORA2A 34/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | ADORA3 105/4885ADORA1 132/4885ADORA2A 34/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | ADORA3 16/4885ADORA1 33/4885ADORA2A 18/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | ADORA3 105/4885ADORA1 132/4885ADORA2A 34/4885 |
| US-20240261316-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, ACE2, MTAP | ADORA3 105/4885ADORA1 132/4885ADORA2A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.